Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma.

MLA

Laukhtina, Ekaterina, et al. “Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma.” European Urology Focus, vol. 8, no. 6, Nov. 2022, pp. 1683–86. EBSCOhost, https://doi.org/10.1016/j.euf.2022.04.017.

APA

Laukhtina, E., Hassler, M. R., Pradere, B., Yanagisawa, T., Quhal, F., Rajwa, P., Sari Motlagh, R., König, F., Pallauf, M., Kawada, T., Mostafaei, H., D’Andrea, D., Enikeev, D., & Shariat, S. F. (2022). Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma. European Urology Focus, 8(6), 1683–1686. https://doi.org/10.1016/j.euf.2022.04.017

Chicago

Laukhtina, Ekaterina, Melanie R Hassler, Benjamin Pradere, Takafumi Yanagisawa, Fahad Quhal, Pawel Rajwa, Reza Sari Motlagh, et al. 2022. “Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma.” European Urology Focus 8 (6): 1683–86. doi:10.1016/j.euf.2022.04.017.